CN107531674B - 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 - Google Patents

用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 Download PDF

Info

Publication number
CN107531674B
CN107531674B CN201680018639.XA CN201680018639A CN107531674B CN 107531674 B CN107531674 B CN 107531674B CN 201680018639 A CN201680018639 A CN 201680018639A CN 107531674 B CN107531674 B CN 107531674B
Authority
CN
China
Prior art keywords
compound
pyrrolidine
pharmaceutically acceptable
tert
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680018639.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107531674A (zh
Inventor
谢玲红
菲利普·格林·琼斯
凯瑞·L·斯皮尔
诺尔·阿伦·鲍威尔
泰琳·G·阿纳尼亚
瓦迪姆·亚历山德罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pgi Drug Development Corp
Sunovion Pharmaceuticals Inc
Original Assignee
Pgi Drug Development Corp
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pgi Drug Development Corp, Sunovion Pharmaceuticals Inc filed Critical Pgi Drug Development Corp
Priority to CN202010607608.6A priority Critical patent/CN111925360B/zh
Publication of CN107531674A publication Critical patent/CN107531674A/zh
Application granted granted Critical
Publication of CN107531674B publication Critical patent/CN107531674B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680018639.XA 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 Active CN107531674B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010607608.6A CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11
US62/115,064 2015-02-11
PCT/US2016/017539 WO2016130796A1 (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010607608.6A Division CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Publications (2)

Publication Number Publication Date
CN107531674A CN107531674A (zh) 2018-01-02
CN107531674B true CN107531674B (zh) 2020-07-31

Family

ID=55456908

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010607608.6A Active CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
CN201680018639.XA Active CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010607608.6A Active CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Country Status (22)

Country Link
US (4) US9856238B2 (enExample)
EP (2) EP3256466B9 (enExample)
JP (3) JP6657241B2 (enExample)
KR (1) KR102601972B1 (enExample)
CN (2) CN111925360B (enExample)
AU (1) AU2016219253C1 (enExample)
CA (1) CA2976095C (enExample)
CY (1) CY1125198T1 (enExample)
DK (1) DK3256466T3 (enExample)
EA (1) EA201791804A1 (enExample)
ES (2) ES2967643T3 (enExample)
HU (1) HUE058698T2 (enExample)
IL (1) IL253914B (enExample)
MX (2) MX392664B (enExample)
MY (1) MY188160A (enExample)
NZ (1) NZ735011A (enExample)
PH (1) PH12017501422A1 (enExample)
PL (1) PL3256466T3 (enExample)
PT (1) PT3256466T (enExample)
SG (2) SG11201706515QA (enExample)
UA (1) UA122222C2 (enExample)
WO (1) WO2016130796A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3256476T3 (pl) * 2015-02-11 2019-05-31 Pgi Drug Discovery Llc Związki i analogi fuzyjnego dihydro-4h-pirazolo[5,1-c][1,4]oksazynylu w leczeniu zaburzeń oun
DK3256466T3 (da) * 2015-02-11 2022-05-02 Sunovion Pharmaceuticals Inc 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser
CN110087687A (zh) 2016-07-29 2019-08-02 赛诺维信制药公司 化合物、组合物及其用途
CA3032302A1 (en) 2016-07-29 2018-02-01 Taleen G. Hanania Compounds and compositions and uses thereof
EP3645120B1 (en) 2017-06-30 2024-12-11 Chase Therapeutics Corporation Nk-1 antagonist compositions and methods for use in treating depression
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393759A (en) * 1990-05-25 1995-02-28 Akzo N.V. Isochromane derivatives
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
WO2000000487A1 (en) 1998-06-30 2000-01-06 Eli Lilly And Company 5-ht1f agonists
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
MXPA04004368A (es) * 2001-11-08 2004-08-11 Sepracor Inc Metodos para tratar depresion y otros transtornos del sistema nervioso central utilizando desmetil-y didesmetil-metabolitos del citalopram enantiomericamente enriquecidos.
EP1831203A1 (en) * 2004-12-21 2007-09-12 F. Hoffmann-Roche AG Chroman derivatives and uses thereof in the treatment of cns disorders
RU2007139541A (ru) 2005-04-22 2009-05-27 Вайет (Us) Производные хромана и хромена и их применение
KR20080090545A (ko) * 2006-01-27 2008-10-08 에프. 호프만-라 로슈 아게 Cns 장애 치료용 2-이미다졸의 용도
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
SG10201401661RA (en) * 2009-12-04 2014-07-30 Sunovion Pharmaceuticals Inc Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders
WO2012122340A1 (en) 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
DK3256466T3 (da) * 2015-02-11 2022-05-02 Sunovion Pharmaceuticals Inc 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393759A (en) * 1990-05-25 1995-02-28 Akzo N.V. Isochromane derivatives
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Asymmetric routes towards polyfunctionalized pyrrolidines:application to the synthesis of alkaloid analogues;Martial Toffano, et al.;《Tetrahedron: Asymmetry》;20131231;3365-3370 *

Also Published As

Publication number Publication date
AU2016219253B2 (en) 2020-10-01
MX2017010363A (es) 2018-05-04
JP7023994B2 (ja) 2022-02-22
HUE058698T2 (hu) 2022-09-28
EA201791804A1 (ru) 2018-02-28
EP4046995C0 (en) 2023-09-13
US9856238B2 (en) 2018-01-02
US10336732B2 (en) 2019-07-02
US20170001987A1 (en) 2017-01-05
MX2020001157A (es) 2022-05-27
CN107531674A (zh) 2018-01-02
US20180093974A1 (en) 2018-04-05
ES2911910T9 (es) 2022-08-12
EP4046995B1 (en) 2023-09-13
EP4046995A1 (en) 2022-08-24
IL253914B (en) 2021-09-30
CA2976095A1 (en) 2016-08-18
MX392664B (es) 2025-03-24
US20190389845A1 (en) 2019-12-26
US20220185799A1 (en) 2022-06-16
MX371404B (es) 2020-01-29
CA2976095C (en) 2023-10-17
JP6657241B2 (ja) 2020-03-04
JP2020079282A (ja) 2020-05-28
SG11201706515QA (en) 2017-09-28
CN111925360B (zh) 2024-03-22
MY188160A (en) 2021-11-24
PT3256466T (pt) 2022-05-10
KR20170129730A (ko) 2017-11-27
SG10201806809QA (en) 2018-09-27
CN111925360A (zh) 2020-11-13
AU2016219253A1 (en) 2017-09-21
BR112017017354A2 (pt) 2018-04-10
EP3256466B9 (en) 2022-07-27
PL3256466T3 (pl) 2022-05-23
UA122222C2 (uk) 2020-10-12
EP3256466A1 (en) 2017-12-20
NZ735011A (en) 2023-07-28
EP3256466B1 (en) 2022-04-06
KR102601972B1 (ko) 2023-11-13
DK3256466T3 (da) 2022-05-02
ES2911910T3 (es) 2022-05-23
CY1125198T1 (el) 2024-12-13
WO2016130796A1 (en) 2016-08-18
US11192885B2 (en) 2021-12-07
AU2016219253C1 (en) 2022-12-08
JP2018505205A (ja) 2018-02-22
PH12017501422A1 (en) 2018-03-19
IL253914A0 (en) 2017-10-31
ES2967643T3 (es) 2024-05-03
JP2022065050A (ja) 2022-04-26

Similar Documents

Publication Publication Date Title
CN107531674B (zh) 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
CN111171047B (zh) 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物
TWI813673B (zh) 抗增生化合物及其用途
CN111183138A (zh) 异色满化合物以及用途
HK40042391A (en) 1-heterocyclyl isochromanyl compounds and analogus for treating cns disorders
HK40078692A (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK40078692B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
BR112017017354B1 (pt) Composto e seu uso, composição, processo para preparar um composto
HK1241876B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK1241876A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
EA046724B1 (ru) Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant